SCHEMBL3407905

SCHEMBL3407905

CCOC(=O)c1nc(-c2ccncc2)c2snc(-c3ccccc3)c2c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 9/20 0.53
DBF4 Q9UBU7 9/20 0.53
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPK1 P28482 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ADORA3 P0DMS8 2/20 0.42
HPGD P15428 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
RARA P10276 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3780077 0.91 CDC7 (0.48) CDC7DBF4ALDH1A1HSD17B10MAPK1
SCHEMBL3401768 0.89 ALDH1A1 (0.49) CDC7DBF4ALDH1A1HSD17B10MAPK1
SCHEMBL3405930 0.88 DHODH (0.48) ALDH1A1HSD17B10NPSR1ADORA3HPGD
SCHEMBL3401461 0.88 ALDH1A1 (0.51) CDC7DBF4ALDH1A1HSD17B10MAPK1
SCHEMBL3407275 0.88 ALDH1A1 (0.51) CDC7DBF4ALDH1A1HSD17B10MAPK1
SCHEMBL3405938 0.88 DHODH (0.49) CDC7DBF4ALDH1A1HSD17B10ADORA3
SCHEMBL3407360 0.87 LMNA (0.44) CDC7DBF4ALDH1A1HSD17B10MAPK1
SCHEMBL3398339 0.85 ALDH1A1 (0.44) CDC7DBF4ALDH1A1HSD17B10MAPK1
SCHEMBL3403370 0.85 ALDH1A1 (0.46) CDC7DBF4ALDH1A1HSD17B10MAPK1
SCHEMBL3401672 0.82 ERCC1 (0.48) ALDH1A1HSD17B10MAPK1HPGDTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9387200-B2 Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity FIBROGEN, INC. (US) 2016-07-12 US disclosed
US-20150209336-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN, INC. 2015-07-30 US disclosed
US-8952160-B2 Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity FIBROGEN, INC. (US) 2015-02-10 US disclosed
EP-2252619-B1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN INC (US) 2013-10-09 EP disclosed
US-20100330199-A1 ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN, INC. 2010-12-30 US disclosed
EP-2252619-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY Fibrogen, Inc. (US) 2010-11-24 EP disclosed
WO-2009089547-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN, INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100330199-A1 ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY HIF1A, HIF1AN, EGLN3 CDC7 2172/4885DBF4 2383/4885ALDH1A1 256/4885
US-20150209336-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY HIF1A, HIF1AN, EGLN3 CDC7 2097/4885DBF4 2434/4885ALDH1A1 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.